Shanghai- and Hong Kong-based Antengene Corporation Limited (SEHK: 6996) announced on June 10, 2026 that China's National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for ATG-201, a CD19 × CD3 bispecific T-cell engager (TCE) with a proprietary steric hindrance masking technology, to proceed into a Phase I clinical trial in patients with B-cell related autoimmune diseases. The trial, named ATTRACT, will be led by Prof. Zhanguo Li (栗占国) of Peking University People's Hospital (PKUPH) and will run in parallel in China and Australia during the first-in-human (FIH) phase, after which global development, manufacturing, and commercialization will transfer to Belgian pharma UCB under an existing worldwide exclusive license agreement.
This is the first bispecific T-cell engager that Antengene has taken into clinical development, and one of the first Chinese-discovered CD19 × CD3 bispecifics cleared globally for an autoimmune indication rather than B-cell malignancy. It also makes Antengene the first Chinese biotech with a CD19 × CD3 bispecific cleared by NMPA, UCB's first Chinese-originated bispecific in its autoimmune pipeline, and Prof. Li's rheumatology group at PKUPH one of the highest-profile Phase I autoimmune bispecific trial sites outside the United States and Western Europe.
For most of the last 25 years, the autoimmune-treatment playbook has been the same: suppress the immune system broadly with corticosteroids, then add a second-line agent (methotrexate, azathioprine, mycophenolate, cyclophosphamide) that takes weeks to months to work and leaves the patient partially immunosuppressed for life. The arrival of rituximab in 2006 — a monoclonal antibody that depletes CD20-positive B cells — was the first targeted biologic for many of these diseases, and it changed practice. But rituximab does not eliminate long-lived plasma cells, does not address CD20-negative B-cell precursors, and relapses are common: in refractory systemic lupus erythematosus (SLE), 40 to 60 percent of rituximab responders relapse within five years, and in ANCA-associated vasculitis the relapse curve is similarly steep.
The newer generation of B-cell-directed therapy goes deeper. Belimumab (Benlysta, GlaxoSmithKline) inhibits the B-lymphocyte stimulator (BLyS) and was approved for SLE in 2011 — the first biologic lupus drug in half a century. Anifrolumab (Saphnelo, AstraZeneca) targets the type I interferon receptor and was approved in 2021. Voclosporin (Lupkynis, Aurinia) brought a calcineurin inhibitor into the lupus nephritis regimen in 2021. None of these drugs are curative. Patients still cycle through steroids, still relapse, still progress to end-organ damage.
The conceptual breakthrough of the last five years has been the recognition that deep B-cell depletion — closer to a reset than a suppression — can induce durable drug-free remission in refractory autoimmune disease. The most dramatic evidence has come from academic CAR-T programs. In 2021, a team at University Hospital Erlangen in Germany reported the first use of CD19 CAR-T cells — the same modality used in B-cell leukemia and lymphoma — in a patient with refractory SLE. The patient went into drug-free remission. By 2024, follow-up cohorts from Erlangen, from Stanford (under Dr. Mackensen), and from a handful of other academic centers had shown similar results in lupus, in systemic sclerosis, in immune-mediated necrotizing myopathy, and in antisynthetase syndrome. The signal was clear: deeper B-cell depletion, longer drug-free remissions, fewer relapses.
CAR-T, however, is autologous, logistically heavy, and expensive — typically $300,000 to $1.5 million per patient in the United States, $80,000 to $200,000 in China. The natural next question — and the one that has consumed autoimmune-biopharma R&D budgets for the last three years — is whether off-the-shelf bispecific antibodies can deliver the same depth of B-cell depletion as CAR-T, without the cell-therapy infrastructure. A CD19 × CD3 bispecific T-cell engager redirects any nearby T cell to a CD19-expressing B cell, lysing it on contact. The drug is bottled, not manufactured per patient. The question is whether it can be made safe enough to use in autoimmune disease, where the patient is not dying of cancer and the tolerance for toxicity is much lower than in oncology.
The existing benchmark for a CD19 × CD3 bispecific is blinatumomab (Blincyto, Amgen), approved in 2014 for B-cell acute lymphoblastic leukemia. Blinatumomab works — it produces deep B-cell aplasia, and in the right patient it can put B-ALL into remission. The problem is that it does not discriminate between malignant B cells and healthy B cells, and it engages CD3 on any T cell that wanders past, which produces cytokine release syndrome (CRS) — the constellation of fever, hypotension, hypoxia, and in severe cases multi-organ dysfunction that has become the signature adverse event of T-cell-engaging therapies. Blinatumomab is administered as a continuous intravenous infusion over 28 days per cycle precisely because the developers found that bolus dosing produced unacceptable CRS rates.
ATG-201, by design, is supposed to be a quieter molecule. The proprietary steric hindrance masking technology keeps the CD3-binding arm of the bispecific occluded — wrapped, in effect, in a steric shield — until the CD19-binding arm grabs a B cell. The act of B-cell engagement changes the antibody's local geometry and unmasks the CD3 arm, which can then recruit a T cell. In cell-culture and preclinical models, this design has been shown to dramatically reduce the tonic CD3 engagement that drives off-target CRS, while preserving on-target cytotoxic potency once the antibody is anchored to a B cell. The result, in principle, is a drug that kills B cells where it finds them and stays quiet where it does not.
If the design works the way Antengene and UCB hope, ATG-201 should be tolerable as a short infusion or subcutaneous injection, not a 28-day continuous IV line. The depth of depletion should be comparable to what CAR-T achieves — which is the point. And the price, if it follows the pattern of branded bispecifics for autoimmune disease rather than for oncology, should be in the high five to low six figures per year in Western markets, with substantially lower pricing tiers in China and other emerging markets. That would put deep B-cell depletion within reach of patients who today are stuck on chronic steroids, or who cannot afford the cell-therapy option, or who do not have access to an academic CAR-T-for-autoimmune program at all.
A bispecific T-cell engager is, in its simplest form, two single-chain variable fragments (scFvs) — the antigen-binding tips of an antibody — spliced together by a flexible linker. One scFv binds the target antigen (in ATG-201's case, CD19 on the surface of a B cell). The other binds CD3, a component of the T-cell receptor complex. When both engagements happen on adjacent cells, the T cell receives an activating signal and lyses the B cell. This is the same conceptual mechanism that drives blinatumomab and the BCMA-directed bispecifics used in multiple myeloma (teclistamab, talquetamab, elranatamab).
The wrinkle is the CD3 arm. CD3 is expressed on essentially all T cells, and T cells are everywhere. In a typical dosing scenario for an unmasked CD3-bispecific, the drug finds a T cell long before it finds a B-cell target, and the resulting stray T-cell activation is what produces the cytokine release. In oncology, the drug is given to patients who have visible tumor burden, and the tolerable CRS rate is the price of treatment. In autoimmune disease, the calculation is different: the B cells being depleted are a tiny minority of the total body B-cell pool (mostly in lymph nodes and bone marrow, not in the blood where the drug concentration is highest), and the patient is not at immediate risk of death from their disease. CRS has to be near zero.
The steric hindrance mask is the engineering answer. The CD3-binding scFv is wrapped in a small peptide or protein domain — the "mask" — that physically blocks the CD3-binding site from engaging CD3. The mask is attached to the rest of the molecule in a way that lets it swing out of the way when the CD19 arm binds a B cell. Antengene has not published the exact structure of the mask (patent applications are pending), but the concept has been used by other developers in the bispecific space — most notably in masked cytokine fusion proteins and in masked T-cell-engager programs at larger Western biotechs.
The functional consequence, if the preclinical data hold up, is a much wider therapeutic window. ATG-201 can be dosed at concentrations that would produce severe CRS in an unmasked molecule, because the CD3 arm is essentially inert until it gets close to a B cell. Once the CD19 arm binds, the mask swings away, the CD3 arm engages, and the T cell is activated. The result is a localized cytotoxic event rather than a systemic inflammatory one.
Antengene's IND-enabling package — the data set that the NMPA reviewed before clearing the trial — includes standard preclinical milestones: in vitro potency against CD19-positive B-cell lines, dose-dependent B-cell depletion in non-human primate studies, pharmacokinetic profiles supporting intermittent dosing, and toxicology studies that did not show off-target organ effects at the projected human therapeutic dose. The company has not, in the public materials, released a head-to-head comparison with blinatumomab in the same preclinical model. That kind of cross-molecule comparison is typically held back for a later publication or a future scientific meeting, and is not required for an IND filing.
The ATTRACT study is a standard first-in-human Phase I, structured as a dose escalation followed by a dose expansion, with the goal of finding the recommended Phase 2 dose (RP2D) and getting an early read on safety and biological activity. Antengene has not, in the press materials released on June 10, disclosed the specific indications that will be enrolled at the dose-expansion stage, the sample size, or the projected enrollment timeline. The IND clearance allows the trial to start; the design specifics are typically published on ClinicalTrials.gov and ChiCTR (the Chinese clinical trial registry) within a few weeks of the first site opening.
What is known from the press release:
Industry-standard dose-escalation cohorts for a bispecific TCE in autoimmune disease run 3 to 6 patients per cohort, with 4 to 6 cohorts across the dose range, for a total of 20 to 40 patients in dose escalation. The dose-expansion phase at the RP2D typically enrolls an additional 20 to 40 patients in one or two specific indications. Antengene has not confirmed the design, but the company has indicated that enrollment is expected to begin in the second half of 2026, with first-patient-in likely in Q3 or Q4 2026, depending on site activation.
If the trial enrolls on a typical autoimmune Phase I timeline — 12 to 18 months for dose escalation, another 6 to 12 months for dose expansion — the initial human data set would be available to UCB in late 2027 or 2028. UCB would then design the Phase II registrational program, which for an autoimmune bispecific typically runs 18 to 24 months in a single indication and could support a first approval in 2030 or 2031, with subsequent label expansion.
Peking University People's Hospital (PKUPH, 北京大学人民医院) is one of the top-ranked tertiary hospitals in northern China, and its Department of Rheumatology and Immunology is consistently ranked among the top three rheumatology programs in the country. The department is led clinically by Prof. Zhanguo Li (栗占国), a senior Chinese rheumatologist with a research portfolio spanning systemic lupus erythematosus, rheumatoid arthritis, and immune-mediated cytopenias. Prof. Li has published extensively on refractory autoimmune disease and is one of the principal investigators on a number of China-based clinical trials of novel immunomodulatory agents.
For Antengene, the choice of PKUPH as the lead Phase I site is a credibility move. A bispecific TCE for autoimmune disease is the kind of program where a Phase I site with deep clinical-trial experience in the indication is a precondition for clean data. PKUPH's rheumatology department enrolls patients across the full range of B-cell related autoimmune diseases, has its own translational research infrastructure, and runs an International Patient Office (the hospital's international services arm) that handles referral paperwork, translation of medical records, and visa invitation letters for foreign patients on clinical-trial slots.
For an international patient who might consider enrolling in the ATTRACT trial at PKUPH, the practical pathway is the same as for any other clinical trial at a top Chinese academic hospital:
Antengene's partnership with UCB is the part of the story that most clearly signals the asset's potential. UCB is a Brussels-based pharmaceutical company that has spent the last decade positioning itself as a global specialist in immune-mediated inflammatory diseases and rare neurological conditions. The company's autoimmune-neuro pipeline is anchored by three approved drugs: Cimzia (certolizumab pegol, a TNF inhibitor for rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease), Rystiggo (rozanolixizumab, an FcRn antagonist for generalized myasthenia gravis), and Zilbrysq (zilucoplan, a complement C5 inhibitor for myasthenia gravis). All three target immune mechanisms that, in different disease contexts, intersect with B-cell biology.
The strategic logic of the Antengene deal is straightforward: UCB has deep late-stage development capability, a global commercial footprint in autoimmune and neurological disease, and a clear gap in its portfolio for a deep B-cell-depleting bispecific. Acquiring a Phase I-ready, Chinese-discovered CD19 × CD3 TCE with a steric hindrance mask is cheaper and faster than developing one in-house. The deal structure — Antengene runs the FIH trials in China and Australia, UCB takes over for global development, manufacturing, and commercialization — is a standard "China-originated, globally licensed" template that has produced several recent Chinese biotech success stories, including BeiGene's Brukinsa (developed in China, now marketed globally by BeiGene under its own name after the AstraZeneca-style co-development) and the Akeso / Sino Biopharm ivonescimab arrangement.
Press releases for licensing deals typically include upfront payments, milestone payments, and royalty terms, but Antengene and UCB have not, in the materials released on June 10, disclosed specific financial terms of the ATG-201 license. The deal was originally announced in 2024 (when UCB acquired worldwide rights to the program), and the financial terms are usually subject to confidentiality clauses in the original licensing agreement. What can be inferred: the deal was structured to give Antengene enough runway to run the FIH program and transfer a clean data package to UCB, and the economics for Antengene are typically back-loaded — milestone payments on Phase II initiation, Phase III initiation, first approval, and post-approval sales milestones, plus royalties on global sales. For a Phase I autoimmune bispecific, this is a standard structure.
What the deal does signal is that UCB — a global pharma with a deep autoimmune and neuro franchise — has confidence in the molecule's preclinical data and in Antengene's ability to run a clean FIH program. That is not a guarantee of clinical success, but it is a meaningful credibility marker for a Chinese biotech asset at this stage of development.
For international patients, the practical question is whether coming to Beijing — rather than going to a Western academic medical center — is a realistic option for refractory autoimmune care. The answer depends on the indication and on the patient's insurance situation, but for self-pay patients with refractory disease who have exhausted their home-country options, Beijing and Shanghai have become genuine tertiary referral destinations.
PKUPH is one of three Beijing hospitals that have a serious international practice in autoimmune disease. Peking Union Medical College Hospital (PUMCH, 北京协和医院) is the other top-tier option — its rheumatology and immunology department is consistently ranked #1 in China and has a long history of treating complex autoimmune cases from across Asia and the Middle East. China-Japan Friendship Hospital is the third, with a strong immunology program but a smaller international patient office.
For patients considering enrollment in a clinical trial at one of these centers, the key practical considerations are:
Shanghai has emerged as the dominant Chinese hub for cell therapy — the Jiahui / Ruijin / Fudan Shanghai Cancer Center cluster, the Zhangjiang biotech ecosystem, and the Hainan Boao Lecheng medical-tourism pilot zone for unapproved therapies are all Shanghai-anchored. For autoimmune disease specifically, however, Beijing has the deeper rheumatology bench. The two major CAR-T-for-autoimmune programs in China are at PUMCH and at PKUPH, and the trial experience with deep B-cell depletion in non-malignant disease is concentrated in these two Beijing centers. International patients whose primary need is refractory autoimmune care — and who are weighing Shanghai versus Beijing — will generally find a deeper rheumatology bench in Beijing, with the corollary trade-off that the cell-therapy infrastructure in Shanghai is more developed for oncologic indications.
Blinatumomab, the only currently approved CD19 × CD3 bispecific, runs roughly $178,000 per treatment course in the United States for B-ALL — and that does not include the hospital costs of the 28-day continuous infusion, which typically add another $50,000 to $100,000. In the autoimmune space, the newer bispecifics (Sanofi's frexalimab in multiple sclerosis, the anti-CD20 and anti-BCMA bispecifics in lupus trials) are projected to price in the $150,000 to $300,000 per patient per year range if they reach Western approval, on a par with other branded specialty-biologic autoimmune drugs.
China prices these drugs very differently. CAR-T therapies that cost $300,000 to $1.5 million in the US are typically available in China for $80,000 to $200,000 — and Chinese commercial CAR-T products for B-cell lymphoma are now covered by the China National Healthcare Security Administration's medical-insurance program for selected indications. If ATG-201 follows a similar trajectory, the Chinese-domestic price point for the drug itself is likely to be in the $30,000 to $80,000 per patient per year range once it is approved by NMPA, and substantially lower than that for patients covered by Chinese national insurance.
For international patients, the practical access routes in the near term are:
If you or a family member has refractory B-cell autoimmune disease — lupus that has relapsed on belimumab, vasculitis that has relapsed on rituximab, immune thrombocytopenia that has failed splenectomy, or any of the other conditions for which deep B-cell depletion is biologically rational — and you are considering coming to China for evaluation, enrollment in ATTRACT, or other advanced care, the practical workflow is as follows:
Before contacting any hospital, make sure the medical record is complete. You will need: the original diagnostic workup (with the specific diagnostic criteria met — 2019 EULAR/ACR for SLE, ACR/EULAR for vasculitis, etc.), the prior treatment history with dates and outcomes, and recent disease activity scores. The clearer and more complete the record, the faster the pre-screen can move.
For B-cell autoimmune disease with a clinical-trial angle, the three top Beijing options are PUMCH, PKUPH, and China-Japan Friendship Hospital. For pure cell-therapy access (existing CAR-T products), Shanghai is the deeper ecosystem — see our earlier pieces on Jiahui International Cancer Center's international CAR-T program and the Shanghai cell-therapy corridor for context.
Email is the standard first contact. A useful pre-screening email includes: the diagnosis, the current disease activity score, the prior treatment history, a one-paragraph summary of the patient's current functional status, and an explicit question about whether the team is open to international enrollment in the ATTRACT trial (or in a related bispecific program).
A Phase I autoimmune bispecific trial at a Beijing academic center requires 4 to 8 weeks of on-site presence for screening, dosing, and the immediate post-dose monitoring period. Plan for an accompanying family member, for English-language hospital coordination, and for the possibility of extended stay if the protocol requires more intensive monitoring than expected. Hotel and long-stay apartment options near PKUPH (in the Xicheng district, central Beijing) are plentiful.
If the patient is currently on corticosteroids, mycophenolate, or other immunosuppressants, the trial protocol will require a washout period before the first dose. The hospital's rheumatology team can coordinate a bridging regimen with the patient's home rheumatologist to keep the disease under control during the washout and travel period.
If the patient benefits from the trial, ask the trial team about the rollover / long-term extension protocol — most Phase I autoimmune bispecific programs include one. If the patient does not enroll in a rollover phase, the hospital's rheumatology team can continue to manage the case in their standard international patient clinic, and the patient can be transitioned to whatever commercial therapy is available in their home country.
The Antengene ATG-201 announcement is a small story in the short run and a potentially large one in the long run. The short-run story is that NMPA cleared an IND for a Chinese-discovered CD19 × CD3 bispecific with a safety-engineered mask, to start a Phase I in autoimmune disease at one of China's top rheumatology centers. The long-run story — the one that will matter for international patients — is whether a deep B-cell-depleting bispecific can deliver CAR-T-like remission depth in refractory autoimmune disease, at a fraction of the cost and logistical overhead.
The next 18 months will be telling. Watch for:
For international patients with refractory autoimmune disease, the bottom line is this: a credible, well-partnered Chinese biotech is now in the global race to develop a deep B-cell-depleting bispecific for autoimmune indications, and the Phase I will be run at one of China's top rheumatology centers. For patients who can navigate the cross-border clinical-trial pathway, the ATTRACT trial at Peking University People's Hospital is one of the earliest and most promising ways to access deep B-cell depletion as a treatment strategy — and it is happening in Beijing, not Boston or Basel.
Considering enrollment in ATTRACT or another advanced autoimmune program in China?
Our team can help with pre-screening, medical-records translation, hospital coordination, and travel logistics for clinical-trial enrollment at PKUPH and other top Chinese academic centers.
Get a Free Pre-Screening Assessment